Key result
Quarterly administration of SHR-1918 produced placebo-adjusted LDL-C reductions of 18.6% to 22.9% and triglyceride reductions of 48.6% to 57.6% at 24 weeks.
Why the study?
Does subcutaneous SHR-1918 administered every 12 weeks reduce LDL-C and triglycerides in adults on stable background lipid-lowering therapy?
Does subcutaneous SHR-1918 administered every 12 weeks reduce LDL-C and triglycerides in adults on stable background lipid-lowering therapy?
Answers are grounded in this paper and cite their sources.
Quarterly dosing of the ANGPTL3 inhibitor SHR-1918 provides sustained reductions in LDL-C and triglycerides, supporting further evaluation for receptor-independent lipid lowering in conditions like homozygous familial hypercholesterolemia.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted an editorial in Dyslipidemia (triglyceride-rich or mixed) (n=44). SHR-1918 vs. Placebo was evaluated on Placebo-adjusted change in LDL-C and triglycerides at 24 weeks (18.6% to 22.9% LDL-C reduction; 48.6% to 57.6% triglyceride reduction). Quarterly administration of SHR-1918 produced placebo-adjusted LDL-C reductions of 18.6% to 22.9% and triglyceride reductions of 48.6% to 57.6% at 24 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: